| Date | Title | Description |
| 16.08.2024 | CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS | BEIJING, Aug. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovat... |
| 19.07.2024 | CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS | BEIJING, July 19, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported ... |
| 08.07.2024 | CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP | BEIJING, July 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces a... |
| 26.06.2024 | CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business... | BEIJING, June 26, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and ... |
| 26.06.2024 | CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He | BEIJING, June 26, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and ... |
| 15.05.2024 | CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP) | BEIJING, May 15, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced today the fol... |
| 14.05.2024 | CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS | BEIJING, May 14, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported f... |
| 11.03.2024 | BioStock: BioInvent’s CEO comments on the study success in China | BioStock: BioInvent’s CEO comments on the study success in China
Mon, Mar 11, 2024 12:31 CET Report this content
BioInvent’s partner in China, CASI Pharmaceuticals, has announced preliminary encouraging efficacy data for BioInvent’s lead dr... |
| 20.01.2022 | CASI PHARMACEUTICALS PARTNER, BIOINVENT, ANNOUNCES BI -1206 GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA | ROCKVILLE, Md and LUND, Sweden, Jan. 20, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announc... |
| 18.01.2022 | CASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA | ROCKVILLE, Md. and BEIJING, Jan. 18, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced t... |
| 03.01.2022 | CASI PHARMACEUTICALS, RECEIVES NASDAQ DEFICIENCY NOTICE | ROCKVILLE, Md. and BEIJING, Jan. 3, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announ... |
| 17.12.2021 | CASI PHARMACEUTICALS ANNOUNCES STOCK REPURCHASE PROGRAM | ROCKVILLE, Md. and BEIJING, Dec. 17, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), (the "Company" or "CASI"), a U.S. biopharmaceutical company focused on developing and commercializing innovative therap... |
| 17.12.2021 | CASI Pharmaceuticals, Inc. announces an Equity Buyback for $10 million worth of its shares. | CASI Pharmaceuticals, Inc. (NasdaqCM:CASI) announces a share repurchase program. Under the program, the company will repurchase up to $10 million worth of its shares. The repurchases will be paid from available corporate funds, including ca... |
| 10.12.2021 | CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE CTA APPROVAL FOR CLINICAL STUDY OF BI-1206 IN NHL IN CHINA | ROCKVILLE, Md. and BEIJING, Dec. 10, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today annou... |
| 15.11.2021 | CASI Pharmaceuticals To Present At Jefferies London Healthcare Conference | ROCKVILLE, Md., and BEIJING, Nov. 15, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today anno... |
| 12.11.2021 | CASI Pharmaceuticals Announces Third Quarter 2021 Financial Results | ROCKVILLE, Md. and BEIJING, Nov. 12, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today re... |
| 26.10.2021 | CASI Pharmaceuticals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) For Acceleration Of CNCT19 Pivotal Trials And Commercialization | ROCKVILLE, Md. and BEIJING - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, reported that Juventas Cell Therapy Ltd.... |
| 25.10.2021 | CASI Pharmaceuticals : Pharmaceuticals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) For Acceleration Of CNCT19 Pivotal Trials And Commercialization | ROCKVILLE, Md. and BEIJING, Oct. 25, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today repor... |
| 25.10.2021 | CASI Pharmaceuticals Announces Partner Juventas Completion Of Series C Financing Of $63 Million For Acceleration Of CNCT19 Pivotal Trials And Commercialization | CASI Pharmaceuticals, Inc., a US biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, reported that Juventas Cell Therapy Ltd. has completed a Series C financing round thro... |
| 12.08.2021 | CASI Pharmaceuticals : Announces Second Quarter 2021 Financial Results | ROCKVILLE, Md. and BEIJING, Aug. 12, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today repor... |
| 12.08.2021 | CASI Pharmaceuticals Announces Second Quarter 2021 Financial Results
USA - English USA - English | |
| 10.06.2021 | CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma | |
| 10.06.2021 | CASI PHARMACEUTICALS, INC.
CASI Pharmaceuticals : Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma | CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma
ROCKVILLE, Md. and BEIJING, June 10, 2021 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmac... |
| 08.06.2021 | CASI PHARMACEUTICALS, INC.
CASI Pharmaceuticals : 2021 Definitive Additional Soliciting Materials | CASI PHARMACEUTICALS, INC.
SUPPLEMENT DATED JUNE 7, 2021
TO THE PROXY STATEMENT DATED MAY 10, 2021
FOR THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JUNE 15, 2021
On May 10, 2021, CASI Pharmaceuticals, Inc. (the "Company") file... |
| 13.05.2021 | CASI Pharmaceuticals Announces First Quarter 2021 Financial Results | |
| 11.05.2021 | CASI PHARMACEUTICALS, INC.
CASI Pharmaceuticals : 2020 Form 10-K Amendment No.1 | UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-K/A
(Amendment No. 1)
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020
OR
TRAN... |
| 30.03.2021 | CASI Pharmaceuticals Announces Full Year 2020 Financial Results | |
| 24.03.2021 | CASI Pharmaceuticals Announces Pricing Of $32,500,000 Public Offering Of Common Stock | |
| 23.03.2021 | CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock | |
| 16.02.2021 | CASI Pharmaceuticals Announces Preliminary Fourth Quarter And Full-Year 2020 Revenues And Provides Business Updates | |
| 28.01.2021 | CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin's Lymphoma Patients | |
| 21.01.2021 | CASI Pharmaceuticals Partner, BioInvent, To Host Key Opinion Leader Call On BI-1206 For Relapsed Or Refractory Non-Hodgkin's Lymphoma | |
| 08.01.2021 | CASI Pharmaceuticals, Inc. To Present At H.C. Wainwright Bioconnect Conference | |
| 23.12.2020 | CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy Designation | |
| 16.12.2020 | CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer | |
| 18.11.2020 | CASI Pharmaceuticals Announces Partner Juventas Completes $65 Million Financing And Initiates Registration Study For CNCT19 (CD19 CAR-T) | |
| 27.10.2020 | BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region | |
| 29.09.2020 | CASI Pharmaceuticals Announces Restructuring of Partnership with Juventas Cell Therapy Ltd | |
| 17.06.2019 | A unicorn stalks Wall Street in search of IPO cash; CASI Pharma in-licenses CD19 therapy from China’s Juventas | → A herd of upstart biotechs will look to Wall Street for some major windfalls this week as a burst of new offerings continues to feed cash into the R&D system. Today we learned that BridgeBio will look to raise in the neigh... |
| 31.01.2019 | Multi-target drugs should be in the pharma pipeline along with precision drugs | Precision medicine — providing the right treatment, for the right patient, at the right time — is saving lives. The use of therapies that home in on single targets is helping beat tough-to-treat diseases that were often deadly in the past.
... |
| 17.09.2018 | Here’s a look at Maryland’s publicly-traded biotech companies | When talk turns to Maryland’s biotech bonafides, the ideas and talent being produced by government institutions like NIH, and research-oriented universities with connected health systems such as Johns Hopkins and University of Maryland are ... |
